Treatment of Chronic Relapsing Urinary Tract Infection With Bacteriophages in Renal Transplant Patients
Overview
- Phase
- Phase 3
- Status
- Terminated
- Enrollment
- 5
- Locations
- 1
- Primary Endpoint
- Urine culture
Overview
Brief Summary
Urinary tract infections (UTIs) with extended-spectrum -lactamase (ESBL)-positive Enterobacteriums (ESBL-E) are a common infectious complication of renal transplant recipients, with 10% of patients suffering from UTIs with ESBL-E within the first year posttransplant. Moreover, recurrence rates of UTI caused by ESBL-E are almost three times higher than those by cephalosporin-susceptible Enterobacteriums demonstrating the decreased efficacy of antibiotics in the treatment of these UTIs.
Detailed Description
According to each patient's urine culture, resistant urinary tract infections will be treated with specific phages and patients will be followed up with their urine cultures for response to therapy.
Study Design
- Study Type
- Interventional
- Allocation
- Na
- Intervention Model
- Single Group
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Stable Kidney Transplant Recipients
- •Stable Immunosupression Dose
- •Stable Renal Function
- •Resistant Urinary Infection with Positive UC
Exclusion Criteria
- •Rejection periods
- •Frail Patients
Arms & Interventions
UC Positives
Stable Transplanted Patients with Positive UC
Intervention: Phage (Biological)
Outcomes
Primary Outcomes
Urine culture
Time Frame: 1 week after administration
Negative Urine Culture
Secondary Outcomes
No secondary outcomes reported
Investigators
nooshin dalili
Assistant Professor
Shahid Beheshti University of Medical Sciences